Skip to main content

Table 3 Demographic characteristics of subjects with and without ESBL-producing E. coli acquisition during travel, number (%) of subjects (N = 58)

From: Antimicrobial resistance acquisition after international travel in U.S. travelers

  Non-ESBL E. coli (n = 53) ESBL-producing E. coli (n = 5)
Male gender 23 (43) 1 (20)
Age, median (minimum-maximum) 63 (15–82) 67 (58–81)
Regiona
 Mexico, Caribbean, & Central America 17 (32) 1 (20)
 Asia 15 (28) 2 (40)
 Africa 15 (28) 1 (20)
 Europe 5 (9) 0
 South America 1 (2) 1 (20)
 North America 2 (4) 0
Purpose of travela
 Vacation 40 (76) 3 (60)
 Visiting friends and relatives 10 (19) 0
 Other (missionary/volunteer)* 3 (6) 2 (40)
 Deployment and military duty 4 (8) 0
 School 1 (2) 0
Duration of travel, median (minimum-maximum) 12 (6–105) 11 (7–16)
Living conditionsa
 Hotel 33 (62) 3 (60)
 Friends and relatives 12 (23) 1 (20)
 Group livingb 9 (17) 1 (20)
 Boat/cruise 7 (13) 0
Local water ingestion during travel 26 (49) 1 (20)
Water exposures during travel 19 (36) 1 (20)
Antibiotic exposure since enrollment 20 (38) 3 (60)
 Malaria chemoprophylaxis 19 (36) 3 (60)
  Atovaquone/Proguanil 14 (26) 3 (60)
  Doxycycline 3 (6) 0
  Chloroquine 2 (4) 0
 Antibiotics for traveler’s diarrhea since enrollment 2 (4) 1 (20)
  Ciprofloxacin 1 (2) 1 (20)
  Erythromycin 1 (2) 0
 Systemic antibiotics for other indications since enrollment 2 (4) 1 (20)
  Azithromycin 1 (2) 0
  Cephalexin 1 (2) 0
  Unknown antibiotic 0 1 (20)
Illness since enrollment 11 (21) 2 (40)
Duration of illness, median (minimum-maximum) 4 (1–27) 5 (2–8)
  1. aPercentages greater than 100 as someone can be counted more than once based upon region of travel or living conditions
  2. bGroup living included barracks, dorms, or kibbutz
  3. * p = 0.05